{"id":"NCT03896477","sponsor":"PATH","briefTitle":"Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants","officialTitle":"A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's 10-Valent Pneumococcal Conjugate Vaccine (PNEUMOSILÂ®) Administered in a 2+1 Schedule to Healthy Infants in The Gambia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-18","primaryCompletion":"2020-12-17","completion":"2020-12-17","firstPosted":"2019-04-01","resultsPosted":"2022-04-20","lastUpdate":"2022-04-20"},"enrollment":660,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumonia, Pneumococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumosil","otherNames":["Serum Institute of India Pneumococcal conjugate vaccine (SIIPL-PCV )"]},{"type":"BIOLOGICAL","name":"Prevenar 13","otherNames":[]},{"type":"BIOLOGICAL","name":"Synflorix","otherNames":["Pneumococcal polysaccharide conjugate vaccine (adsorbed)"]}],"arms":[{"label":"Pneumosil","type":"EXPERIMENTAL"},{"label":"Synflorix","type":"ACTIVE_COMPARATOR"},{"label":"Prevenar 13","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objectives of this study are to evaluate the immunogenicity (antibody response) and safety and tolerability of a 2-dose primary series and booster dose (2+1 schedule) of Pneumosil co-administered with routine pediatric vaccines in healthy infants in The Gambia.","primaryOutcome":{"measure":"Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies Four Weeks Post-Booster","timeFrame":"4 weeks post booster dose","effectByArm":[{"arm":"Pneumosil","deltaMin":8.45,"sd":null},{"arm":"Synflorix","deltaMin":2.9,"sd":null},{"arm":"Prevenar 13","deltaMin":5.87,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":1,"countries":["The Gambia"]},"refs":{"pmids":["36638819"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":220},"commonTop":["Upper respiratory tract infection","Irritability postvaccinal","Pyrexia","Vaccination site pain","Diarrhoea"]}}